Skip to main content
Independent and nonpartisan. SaveYourState is a civic information resource. It is not a government website and is not affiliated with any government agency, party, or campaign.

Kentucky · 2026 Regular Session · Bill

HB 543: AN ACT relating to the use of experimental treatments for life-threatening or severely debilitating illness.

In committee Official data

  1. Introduced
  2. In committee
  3. Passed one chamber
  4. Passed both chambers
  5. Enacted

Last official action: ·Record last updated:

Plain-language summary

HB 543 is a bill introduced in the Kentucky House on February 3, 2026. According to its official title, it concerns: AN ACT relating to the use of experimental treatments for life-threatening or severely debilitating illness. Most recent recorded action (February 10, 2026): to Health Services (H).

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written

Official summary

Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.

Create a new section of KRS Chapter 217 to define terms; permit a manufacturer operating within an eligible facility to make available to an eligible patient an individualized investigational drug, biological product, or device; permit the manufacturer to provide the individualized investigational drug, biological product, or device or require the patient to cover the costs; provide that if a patient dies while being treated his or her heirs are not liable for costs; provide that health care provider licensing boards may not take actions against licensees for their recommendations relating to an individualized investigational drug, biological product, or device; provide that official attempts shall not be made to block an eligible patient's access to an individualized investigational drug, biological product, or device; prohibit private actions against a manufacturer of an individualized investigational drug, biological product, or device that has exercised reasonable care in accordance with this section; preclude any conclusion that health insurance coverage is required or that hospitals are required to provide new or additional services.

Sponsors

NameRolePartyChamberDistrict
No sponsor recorded in source data.

“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.

Recent official actions

  1. to Health Services (H)
  2. to Committee on Committees (H)
  3. introduced in House

Sources

  1. Open States / Plural (data from the official legislature website)
  2. Official legislature source